Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free AGIO Stock Alerts

Agios Pharmaceuticals (AGIO) Financials

Agios Pharmaceuticals logo
$33.56 +0.09 (+0.27%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$33.58 +0.02 (+0.04%)
As of 08/14/2026 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Agios Pharmaceuticals

Annual Income Statements for Agios Pharmaceuticals

This table shows Agios Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -118 -198 -315 -346 -411 -327 1,605 -232 -352 674 -413
Consolidated Net Income / (Loss)		 -118 -198 -315 -346 -411 -327 1,605 -232 -352 674 -413
Net Income / (Loss) Continuing Operations		 -118 -198 -315 -346 -301 -329 -357 -232 -352 680 -411
Total Pre-Tax Income 		-118 -198 -315 -346 -301 -329 -357 -232 -352 718 -414
Total Operating Income		 -119 -201 -321 -362 -316 -336 -378 -389 -391 -426 -472
Total Gross Profit		 59 70 43 93 0.00 0.00 0.00 13 24 32 48
Total Revenue		 59 70 43 94 0.00 0.00 0.00 14 27 36 54
Operating Revenue		 59 70 43 94 - - 0.00 14 27 36 54
Total Cost of Revenue		 0.00 0.00 0.00 1.40 0.00 0.00 0.00 1.70 2.88 4.17 6.35
Operating Cost of Revenue		 - 0.00 0.00 1.40 - - 0.00 1.70 2.88 4.17 6.35
Total Operating Expenses		 178 271 364 455 316 336 378 402 415 458 520
Selling, General & Admin Expense		 36 51 71 114 102 115 121 122 120 157 180
Research & Development Expense		 142 220 293 341 214 221 257 280 296 301 340
Total Other Income / (Expense), net		 0.97 2.51 6.12 16 15 6.61 22 157 39 1,137 56
Interest & Investment Income		 0.97 2.51 6.12 16 15 6.61 7.48 23 33 48 56
Other Income / (Expense), net		 - - - - - 0.00 14 135 6.06 1,089 0.00
Income Tax Expense		 - - - - - - - 0.00 0.00 44 -1.02
Other Gains / (Losses), net		 - - - - 0.00 - - - - 6.49 1.96
Basic Earnings per Share		 ($3.15) ($5.07) ($6.75) ($6.03) ($6.86) ($4.74) $26.55 ($4.23) ($6.33) $11.86 ($7.12)
Weighted Average Basic Shares Outstanding		 37.43M 39.13M 46.59M 57.42M 59.99M 69.00M 60.45M 54.79M 55.65M 56.81M 57.97M
Diluted Earnings per Share		 ($3.15) ($5.07) ($6.75) ($6.03) ($6.86) ($4.74) $26.55 ($4.23) ($6.33) $11.64 ($7.12)
Weighted Average Diluted Shares Outstanding		 37.43M 39.13M 46.59M 57.42M 59.99M 69.00M 60.45M 54.79M 55.65M 57.89M 57.97M
Weighted Average Basic & Diluted Shares Outstanding		 37.43M 39.13M 46.59M 57.42M 59.99M 69.00M 54.64M 55.29M 56.19M 57.30M 58.59M

Quarterly Income Statements for Agios Pharmaceuticals

This table shows Agios Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -96 -82 -96 948 -97 -89 -112 -103 -108 -99 -101
Consolidated Net Income / (Loss)		 -96 -82 -96 948 -97 -89 -112 -103 -108 -99 -101
Net Income / (Loss) Continuing Operations		 -96 -82 -96 950 -92 -89 -112 -103 -106 -99 -101
Total Pre-Tax Income 		-96 -83 -98 1,001 -104 -89 -113 -103 -107 -99 -101
Total Operating Income		 -106 -92 -106 -103 -125 -107 -127 -117 -122 -110 -111
Total Gross Profit		 6.52 7.56 7.12 8.18 9.47 7.64 11 11 18 19 42
Total Revenue		 7.10 8.19 8.62 8.96 11 8.73 12 13 20 21 45
Operating Revenue		 7.10 8.19 8.62 8.96 11 8.73 12 13 20 21 45
Total Cost of Revenue		 0.59 0.63 1.50 0.78 1.26 1.09 1.70 1.68 1.88 1.32 3.00
Operating Cost of Revenue		 0.59 0.63 1.50 0.78 1.26 1.09 1.70 1.68 1.88 1.32 3.00
Total Operating Expenses		 113 100 113 111 135 114 138 128 140 129 152
Selling, General & Admin Expense		 35 31 36 39 52 42 46 41 52 48 52
Research & Development Expense		 77 69 77 72 83 73 92 87 88 81 101
Total Other Income / (Expense), net		 10 8.89 8.12 1,102 16 17 15 13 12 11 9.85
Interest & Investment Income		 8.62 8.89 8.12 13 18 16 15 13 12 11 9.73
Other Income / (Expense), net		 1.71 - - 1,089 - 1.25 - 0.00 - 0.12 0.12
Basic Earnings per Share		 ($1.71) ($1.45) ($1.69) $16.65 ($1.65) ($1.55) ($1.93) ($1.78) ($1.86) ($1.69) ($1.69)
Weighted Average Basic Shares Outstanding		 55.65M 56.38M 56.80M 56.94M 56.81M 57.46M 57.93M 58.14M 57.97M 58.78M 59.49M
Diluted Earnings per Share		 ($1.71) ($1.45) ($1.69) $16.22 ($1.44) ($1.55) ($1.93) ($1.78) ($1.86) ($1.69) ($1.69)
Weighted Average Diluted Shares Outstanding		 55.65M 56.38M 56.80M 58.43M 57.89M 57.46M 57.93M 58.14M 57.97M 58.78M 59.49M
Weighted Average Basic & Diluted Shares Outstanding		 56.19M 56.77M 56.89M 57.03M 57.30M 57.92M 58.10M 58.31M 58.59M 59.47M 59.70M

Annual Cash Flow Statements for Agios Pharmaceuticals

This table details how cash moves in and out of Agios Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 58 89 -58 -32 10 47 76 -64 -51 -12 13
Net Cash From Operating Activities		 -77 39 -285 -304 -371 -291 -407 -309 -296 -390 -373
Net Cash From Continuing Operating Activities		 -77 39 -285 -304 -236 -244 -314 -309 -296 -390 -373
Net Income / (Loss) Continuing Operations		 -118 -198 -315 -346 -301 -329 -357 -232 -352 674 -413
Consolidated Net Income / (Loss)		 -118 -198 -315 -346 -411 -327 1,605 -232 -352 674 -413
Depreciation Expense		 3.34 5.70 6.43 7.17 8.09 9.79 9.24 8.56 6.62 5.65 5.18
Amortization Expense		 0.54 0.77 -0.01 -3.84 -3.20 3.02 6.95 -1.20 -5.05 -14 -7.20
Non-Cash Adjustments To Reconcile Net Income		 30 45 49 67 61 71 63 -69 60 -1,050 58
Changes in Operating Assets and Liabilities, net		 6.64 185 -26 -28 -0.41 1.97 -37 -16 -5.39 -4.76 -16
Net Cash From Investing Activities		 128 -119 -58 -274 91 76 1,249 243 240 363 377
Net Cash From Continuing Investing Activities		 128 -119 -58 -274 92 77 -554 243 240 363 377
Purchase of Property, Plant & Equipment		 -20 -9.92 -4.63 -6.99 -12 -14 -5.74 -4.88 -1.00 -1.69 -4.32
Purchase of Investments		 -353 -506 -689 -933 -489 -557 -1,378 -1,031 -418 -1,542 -642
Sale of Property, Plant & Equipment		 - - - - - 0.00 0.00 0.96 1.33 0.04 0.00
Divestitures		 - - - - - - - 0.00 0.00 200 0.00
Sale and/or Maturity of Investments		 502 397 635 666 592 648 830 1,146 675 818 1,033
Other Investing Activities, net		 - - - - - 0.00 0.00 132 -18 889 -10
Net Cash From Financing Activities		 6.37 170 285 546 290 262 -766 2.35 5.43 14 8.68
Net Cash From Continuing Financing Activities		 6.37 170 285 546 290 11 -766 2.35 5.43 14 8.68
Issuance of Common Equity		 6.58 170 284 547 290 11 37 2.68 5.43 14 8.68
Cash Income Taxes Paid		 - - - - 0.00 0.00 16 0.00 1.57 43 0.63

Quarterly Cash Flow Statements for Agios Pharmaceuticals

This table details how cash moves in and out of Agios Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 24 31 -34 169 -177 2.72 1.91 12 -3.58 24 -14
Net Cash From Operating Activities		 -72 -100 -73 -84 -133 -111 -77 -88 -96 -119 -57
Net Cash From Continuing Operating Activities		 -72 -100 -73 -84 -133 -111 -77 -88 -96 -119 -57
Net Income / (Loss) Continuing Operations		 -96 -82 -96 948 -97 -89 -112 -103 -108 -99 -101
Consolidated Net Income / (Loss)		 -96 -82 -96 948 -97 -89 -112 -103 -108 -99 -101
Depreciation Expense		 1.40 1.35 1.59 1.35 1.37 1.28 1.26 1.37 1.27 1.36 1.35
Amortization Expense		 -0.39 -2.53 -2.61 -3.73 -5.62 -1.35 -2.42 -1.67 -1.75 -1.14 -1.13
Non-Cash Adjustments To Reconcile Net Income		 13 8.20 18 -1,086 10 10 20 12 13 14 36
Changes in Operating Assets and Liabilities, net		 9.10 -25 6.48 57 -42 -32 17 4.01 -0.28 -34 7.65
Net Cash From Investing Activities		 96 125 37 251 -49 113 79 96 90 141 40
Net Cash From Continuing Investing Activities		 96 125 37 251 -49 113 79 96 90 141 40
Purchase of Property, Plant & Equipment		 -0.23 -0.14 -0.16 -0.42 -0.97 -0.77 -0.88 -1.56 -1.12 -0.77 -1.21
Purchase of Investments		 -90 -244 -105 -996 -198 -175 -131 -175 -161 -148 -152
Sale and/or Maturity of Investments		 186 369 142 158 150 288 221 272 252 290 218
Net Cash From Financing Activities		 0.85 5.86 1.10 2.64 4.84 1.62 0.07 4.44 2.56 2.08 3.15
Net Cash From Continuing Financing Activities		 0.85 5.86 1.10 2.64 4.84 1.62 0.07 4.44 2.56 2.08 3.15
Issuance of Common Equity		 0.85 5.86 1.10 2.64 4.84 1.62 0.07 4.44 2.56 2.08 3.15
Cash Income Taxes Paid		 -0.02 -0.53 -0.08 -0.03 44 0.19 1.32 0.07 -0.94 0.00 0.07

Annual Balance Sheets for Agios Pharmaceuticals

This table presents Agios Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 420 619 614 858 891 853 1,438 1,239 937 1,663 1,297
Total Current Assets		 337 560 445 614 612 637 1,064 833 834 966 942
Cash & Equivalents		 72 161 103 71 81 127 203 139 88 76 89
Short-Term Investments		 245 381 321 515 484 445 817 644 689 817 765
Accounts Receivable		 12 3.43 0.00 5.08 8.95 0.00 4.38 2.21 2.81 4.11 11
Inventories, net		 - - 0.00 0.87 7.33 - 0.00 8.49 19 28 33
Prepaid Expenses		 8.73 10 18 17 24 16 40 39 35 40 44
Other Current Assets		 - 4.89 3.67 5.37 6.37 - - - - - 0.00
Plant, Property, & Equipment, net		 23 25 24 24 31 31 29 23 15 12 11
Total Noncurrent Assets		 60 34 145 220 248 185 345 383 88 686 344
Long-Term Investments		 59 32 144 220 153 98 266 314 29 638 310
Other Noncurrent Operating Assets		 0.61 1.62 0.89 0.24 94 85 78 69 58 48 34
Total Liabilities & Shareholders' Equity		 420 619 614 858 891 853 1,438 1,239 937 1,663 1,297
Total Liabilities		 75 261 239 171 250 453 146 138 126 122 104
Total Current Liabilities		 53 88 95 94 93 94 60 63 68 81 82
Accounts Payable		 15 17 23 18 22 18 17 19 9.78 17 18
Accrued Expenses		 16 32 34 42 53 31 32 30 43 47 45
Other Current Liabilities		 - - 38 33 6.92 7.41 11 14 15 17 18
Total Noncurrent Liabilities		 22 172 144 77 157 359 86 75 58 41 22
Other Noncurrent Operating Liabilities		 - - 126 60 106 97 86 75 58 41 22
Total Equity & Noncontrolling Interests		 345 359 376 688 641 400 1,292 1,101 811 1,541 1,193
Total Preferred & Common Equity		 345 359 376 688 641 400 1,292 1,101 811 1,541 1,193
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Common Equity		 345 359 376 688 641 400 1,292 1,101 811 1,541 1,193
Common Stock		 630 842 1,175 1,794 2,156 2,243 2,334 2,386 2,437 2,494 2,555
Retained Earnings		 -285 -483 -798 -1,105 -1,516 -1,843 -239 -471 -823 -149 -562
Treasury Stock		 - - - - - 0.00 -802 -802 -802 -802 -802
Accumulated Other Comprehensive Income / (Loss)		 -0.32 -0.31 -1.39 -2.17 0.20 0.11 -1.20 -13 -0.44 -1.52 2.19

Quarterly Balance Sheets for Agios Pharmaceuticals

This table presents Agios Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 1,151 1,085 1,007 850 773 1,792 1,556 1,471 1,386 1,185 1,108
Total Current Assets		 792 757 704 664 632 1,074 969 1,019 1,033 835 718
Cash & Equivalents		 104 85 64 119 85 254 79 81 93 114 100
Short-Term Investments		 635 618 583 479 485 751 814 858 860 623 518
Accounts Receivable		 1.78 2.25 1.18 3.45 3.76 3.12 3.34 4.99 5.03 16 20
Inventories, net		 11 16 17 23 24 26 30 31 32 35 30
Prepaid Expenses		 39 37 38 39 35 40 42 45 43 47 46
Other Current Assets		 - - - - - - - - - - 4.10
Plant, Property, & Equipment, net		 21 20 17 14 13 12 11 11 11 11 9.95
Total Noncurrent Assets		 338 308 286 172 128 706 576 441 342 340 381
Long-Term Investments		 272 244 225 116 75 656 531 400 304 308 347
Other Noncurrent Operating Assets		 66 64 61 56 53 50 45 41 38 31 34
Total Liabilities & Shareholders' Equity		 1,151 1,085 1,007 850 773 1,792 1,556 1,471 1,386 1,185 1,108
Total Liabilities		 115 121 120 106 113 165 89 102 101 76 82
Total Current Liabilities		 45 55 58 52 63 119 52 70 75 59 70
Accounts Payable		 8.66 12 13 11 10 17 14 18 20 14 16
Accrued Expenses		 22 29 30 25 37 33 21 35 37 26 35
Other Current Liabilities		 14 14 15 15 16 16 17 18 18 19 19
Total Noncurrent Liabilities		 70 66 62 54 50 46 37 31 27 17 12
Other Noncurrent Operating Liabilities		 70 66 62 54 50 46 37 31 27 17 12
Total Equity & Noncontrolling Interests		 1,037 964 887 744 661 1,627 1,467 1,370 1,284 1,109 1,026
Total Preferred & Common Equity		 1,037 964 887 744 661 1,627 1,467 1,370 1,284 1,109 1,026
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,037 964 887 744 661 1,627 1,467 1,370 1,284 1,109 1,026
Common Stock		 2,399 2,411 2,422 2,452 2,464 2,478 2,507 2,522 2,538 2,573 2,592
Retained Earnings		 -552 -635 -727 -904 -1,000 -52 -238 -350 -454 -661 -762
Treasury Stock		 -802 -802 -802 -802 -802 -802 -802 -802 -802 -802 -802
Accumulated Other Comprehensive Income / (Loss)		 -8.41 -8.87 -5.90 -1.09 -1.05 3.42 0.37 0.66 2.05 -0.31 -1.80

Annual Metrics And Ratios for Agios Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Agios Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -9.55% 18.22% -38.46% 119.45% -100.00% 0.00% 0.00% 0.00% 88.36% 36.07% 48.03%
EBITDA Growth		 -119.84% -69.41% -61.62% -14.24% 13.30% -3.77% -7.64% 28.96% -55.36% 270.52% -172.44%
EBIT Growth		 -119.27% -69.32% -59.61% -12.99% 12.75% -6.21% -8.36% 30.09% -51.48% 272.12% -171.17%
NOPAT Growth		 -119.27% -69.32% -59.61% -12.99% 12.75% -6.21% -12.65% -2.81% -0.63% -45.78% 17.27%
Net Income Growth		 -120.04% -68.58% -58.55% -9.97% -18.91% 20.44% 590.18% -114.45% -51.89% 291.35% -161.27%
EPS Growth		 -98.11% -60.95% -33.14% 10.67% -13.76% 30.90% 660.13% -115.93% -49.65% 283.89% -161.17%
Operating Cash Flow Growth		 -29.65% 150.11% -839.67% -6.73% -21.75% 21.55% -40.09% 24.02% 4.34% -31.68% 4.33%
Free Cash Flow Firm Growth		 -65.03% 145.60% -668.54% -32.68% 19.94% -10.52% -0.65% 7.49% -1.69% -46.89% 13.26%
Invested Capital Growth		 28.53% -598.21% 10.57% 38.68% 35.02% 72.01% 127.33% -34.77% 21.85% 91.69% 221.30%
Revenue Q/Q Growth		 -12.46% 30.73% -23.00% 27.25% -100.00% 100.00% 0.00% 43.40% 11.62% 11.03% 20.62%
EBITDA Q/Q Growth		 -13.22% -8.85% -11.75% -2.05% 24.57% -36.80% -1.56% 35.56% 0.02% 259.44% 1.50%
EBIT Q/Q Growth		 -13.56% -8.95% -11.36% -1.75% 24.11% -36.30% -1.41% 35.53% -0.27% 263.01% 0.73%
NOPAT Q/Q Growth		 -13.56% -8.95% -11.36% -1.75% 24.11% -36.30% -5.43% 1.43% -1.85% 1.84% 0.73%
Net Income Q/Q Growth		 -13.45% -8.69% -11.24% -1.02% -2.63% 1.41% 0.19% 36.13% -60.32% -0.09% -2.87%
EPS Q/Q Growth		 -12.10% -5.41% -7.31% 3.83% -0.15% 3.66% 17.63% -80.77% -60.66% 2.37% -6.27%
Operating Cash Flow Q/Q Growth		 -41.99% -34.92% -8.87% 0.09% -5.53% 13.20% -9.31% 5.48% -2.18% -18.43% 9.01%
Free Cash Flow Firm Q/Q Growth		 -34.38% -27.13% -7.11% -1.54% 17.33% -1,177.58% 40.59% 10.46% -5.97% -12.61% 11.11%
Invested Capital Q/Q Growth		 4.76% 2.79% -0.17% 0.26% 16.90% 91.14% 508.51% -84.17% -67.79% 126.27% 5.70%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 98.52% 0.00% 0.00% 0.00% 88.03% 89.26% 88.59% 88.26%
EBITDA Margin		 -194.22% -278.30% -730.91% -380.50% 0.00% 0.00% 0.00% -1,735.11% -1,431.09% 1,793.43% -877.60%
Operating Margin		 -200.78% -287.57% -745.84% -384.03% 0.00% 0.00% 0.00% -2,732.07% -1,459.52% -1,166.47% -873.87%
EBIT Margin		 -200.78% -287.57% -745.84% -384.03% 0.00% 0.00% 0.00% -1,786.83% -1,436.95% 1,817.63% -873.87%
Profit (Net Income) Margin		 -199.14% -283.97% -731.60% -366.61% 0.00% 0.00% 0.00% -1,627.82% -1,312.63% 1,845.92% -764.01%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 136.52% 99.41% -450.12% 100.00% 100.00% 93.84% 99.75%
Interest Burden Percent		 99.18% 98.75% 98.09% 95.46% 95.30% 98.03% 97.95% 91.10% 91.35% 108.23% 87.64%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.16% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,627.29% -6,465.52% -5,883.24% -1,757.89%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5,630.70% -6,457.32% -5,975.03% -1,751.79%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5,607.92% 6,428.68% 5,940.53% 1,727.70%
Return on Equity (ROE)		 -30.60% -56.41% -85.73% -65.10% -61.97% -62.95% 189.74% -19.38% -36.83% 57.29% -30.20%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,987.86% -5,585.20% -6,485.22% -5,946.11% -1,862.95%
Operating Return on Assets (OROA)		 -26.03% -38.68% -52.01% -49.22% 0.00% 0.00% 0.00% -19.01% -35.43% 51.02% -31.90%
Return on Assets (ROA)		 -25.82% -38.20% -51.02% -46.99% 0.00% 0.00% 0.00% -17.32% -32.36% 51.82% -27.89%
Return on Common Equity (ROCE)		 -30.60% -56.41% -85.73% -65.10% -61.97% -62.95% 189.74% -19.38% -36.83% 57.29% -30.20%
Return on Equity Simple (ROE_SIMPLE)		 -34.11% -55.35% -83.80% -50.33% -64.24% -81.94% 124.21% -21.06% -43.41% 43.72% 0.00%
Net Operating Profit after Tax (NOPAT)		 -83 -141 -225 -254 -221 -235 -265 -272 -274 -400 -330
NOPAT Margin		 -140.55% -201.30% -522.09% -268.82% 0.00% 0.00% 0.00% -1,912.45% -1,021.66% -1,094.58% -611.71%
Net Nonoperating Expense Percent (NNEP)		 -8.22% -12.17% -15.79% -13.44% -24.97% -16.21% 219.04% 3.40% -8.20% 91.79% -6.10%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -24.74% -33.79% -25.93% -27.70%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 1.48% 0.00% 0.00% 0.00% 11.97% 10.74% 11.41% 11.74%
SG&A Expenses to Revenue		 60.88% 72.56% 165.36% 120.93% 0.00% 0.00% 0.00% 854.45% 447.02% 429.57% 333.68%
R&D to Revenue		 239.90% 315.00% 680.48% 361.62% 0.00% 0.00% 0.00% 1,965.66% 1,101.76% 825.49% 628.44%
Operating Expenses to Revenue		 300.78% 387.57% 845.84% 482.55% 0.00% 0.00% 0.00% 2,820.11% 1,548.78% 1,255.06% 962.12%
Earnings before Interest and Taxes (EBIT)		 -119 -201 -321 -362 -316 -336 -364 -254 -385 663 -472
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -115 -195 -314 -359 -311 -323 -348 -247 -384 655 -474
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 7.08 4.89 7.42 3.90 4.39 7.51 1.38 1.40 1.53 1.22 1.33
Price to Tangible Book Value (P/TBV)		 7.08 4.89 7.42 3.90 4.39 7.51 1.38 1.40 1.53 1.22 1.33
Price to Revenue (P/Rev)		 41.33 25.09 64.80 28.42 0.00 0.00 0.00 108.35 46.40 51.35 29.38
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 1.11 0.00 0.00 2.78 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 89.89% 0.00% 0.00% 35.95% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 85.18 116.69 94.14 38.32 14.75
Enterprise Value to Revenue (EV/Rev)		 34.98 16.88 51.60 19.89 0.00 0.00 0.00 31.31 16.34 9.37 7.83
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.52 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.52 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 30.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 27.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.10 -1.35 -1.55 -1.29 -1.15 -1.09 -1.01 -1.00 -1.00 -0.99 -0.99
Leverage Ratio		 1.19 1.48 1.68 1.39 1.32 1.68 1.35 1.12 1.14 1.11 1.08
Compound Leverage Factor		 1.18 1.46 1.65 1.32 1.26 1.64 1.33 1.02 1.04 1.20 0.95
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.11% 0.08% 0.02% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.11% 0.08% 0.02% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 99.90% 99.92% 99.98% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 2.30 2.07 3.70 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 3.24 2.85 4.86 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 18.63 2.90 4.21 7.06 3.89 0.41 7.12 6.26 4.35 11.05 8.18
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.38 6.33 4.69 6.56 6.59 6.74 17.79 13.30 12.27 11.90 11.46
Quick Ratio		 6.21 6.16 4.47 6.31 6.18 6.07 17.12 12.54 11.47 11.06 10.52
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -95 43 -247 -328 -263 -290 -292 -270 -275 -404 -350
Operating Cash Flow to CapEx		 -381.62% 388.93% -6,164.51% -4,357.59% -3,081.33% -2,061.24% -7,094.93% -7,900.89% 0.00% -23,698.54% -8,641.73%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.13 0.13 0.07 0.13 0.00 0.00 0.00 0.01 0.02 0.03 0.04
Accounts Receivable Turnover		 5.79 9.30 0.00 0.00 0.00 0.00 0.00 4.33 10.70 10.55 7.36
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.21 0.18 0.21
Fixed Asset Turnover		 3.99 2.88 1.73 3.87 0.00 0.00 0.00 0.55 1.40 2.70 4.81
Accounts Payable Turnover		 0.00 0.00 0.00 0.07 0.00 0.00 0.00 0.10 0.20 0.32 0.36
Days Sales Outstanding (DSO)		 63.05 39.24 0.00 0.00 0.00 0.00 0.00 84.38 34.13 34.60 49.61
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,746.32 2,045.93 1,741.19
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 5,310.01 0.00 0.00 0.00 3,782.38 1,798.77 1,157.79 1,006.64
Cash Conversion Cycle (CCC)		 63.05 39.24 0.00 -5,310.01 0.00 0.00 0.00 -3,698.00 -18.32 922.73 784.15
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -31 -215 -192 -118 -77 -21 5.86 3.82 4.66 8.93 29
Invested Capital Turnover		 -1.60 -0.57 -0.21 -0.61 0.00 0.00 0.00 2.94 6.33 5.37 2.87
Increase / (Decrease) in Invested Capital		 12 -184 23 74 41 55 27 -2.04 0.84 4.27 20
Enterprise Value (EV)		 2,068 1,180 2,220 1,877 2,095 2,331 499 446 438 342 423
Market Capitalization		 2,444 1,753 2,787 2,683 2,812 3,001 1,785 1,543 1,245 1,874 1,587
Book Value per Share		 $9.17 $8.53 $7.70 $11.82 $10.88 $5.77 $23.79 $20.03 $14.51 $27.02 $20.46
Tangible Book Value per Share		 $9.17 $8.53 $7.70 $11.82 $10.88 $5.77 $23.79 $20.03 $14.51 $27.02 $20.46
Total Capital		 345 359 376 688 641 400 1,292 1,101 811 1,541 1,193
Total Debt		 0.00 0.00 0.00 0.00 0.67 0.33 0.28 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.67 0.33 0.28 0.00 0.00 0.00 0.00
Net Debt		 -376 -574 -568 -805 -717 -670 -1,286 -1,097 -806 -1,532 -1,164
Capital Expenditures (CapEx)		 20 9.92 4.63 6.99 12 14 5.74 3.92 -0.33 1.65 4.32
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -33 -70 -74 -65 -46 -31 -16 -13 -11 -9.27 5.42
Debt-free Net Working Capital (DFNWC)		 284 471 350 520 519 542 1,004 770 766 884 860
Net Working Capital (NWC)		 284 471 350 520 519 542 1,004 770 766 884 860
Net Nonoperating Expense (NNE)		 35 58 90 92 190 92 -1,870 -41 78 -1,073 82
Net Nonoperating Obligations (NNO)		 -376 -574 -568 -805 -717 -421 -1,286 -1,097 -806 -1,532 -1,164
Total Depreciation and Amortization (D&A)		 3.88 6.47 6.42 3.34 4.89 13 16 7.37 1.57 -8.83 -2.02
Debt-free, Cash-free Net Working Capital to Revenue		 -55.08% -99.95% -171.16% -68.89% 0.00% 0.00% 0.00% -91.12% -41.19% -25.39% 10.03%
Debt-free Net Working Capital to Revenue		 481.13% 674.55% 814.49% 551.22% 0.00% 0.00% 0.00% 5,408.31% 2,855.31% 2,423.27% 1,591.48%
Net Working Capital to Revenue		 481.13% 674.55% 814.49% 551.22% 0.00% 0.00% 0.00% 5,408.31% 2,855.31% 2,423.27% 1,591.48%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.15) ($5.07) ($6.75) ($6.03) ($6.86) ($4.74) $26.55 ($4.23) ($6.33) $11.86 ($7.12)
Adjusted Weighted Average Basic Shares Outstanding		 37.85M 42.23M 57.33M 58.40M 68.51M 69.60M 60.45M 54.79M 55.65M 56.81M 57.97M
Adjusted Diluted Earnings per Share		 ($3.15) ($5.07) ($6.75) ($6.03) ($6.86) ($4.74) $26.55 ($4.23) ($6.33) $11.64 ($7.12)
Adjusted Weighted Average Diluted Shares Outstanding		 37.85M 42.23M 57.33M 58.40M 68.51M 69.60M 60.45M 54.79M 55.65M 57.89M 57.97M
Adjusted Basic & Diluted Earnings per Share		 ($3.15) ($5.07) ($6.75) ($6.03) ($6.86) ($4.74) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 37.43M 39.13M 46.59M 57.42M 59.99M 69.00M 54.64M 55.29M 56.19M 57.30M 58.59M
Normalized Net Operating Profit after Tax (NOPAT)		 -83 -141 -225 -254 -221 -235 -265 -272 -274 -400 -330
Normalized NOPAT Margin		 -140.55% -201.30% -522.09% -268.82% 0.00% 0.00% 0.00% -1,912.45% -1,021.66% -1,094.58% -611.71%
Pre Tax Income Margin		 -199.14% -283.97% -731.60% -366.61% 0.00% 0.00% 0.00% -1,627.82% -1,312.63% 1,967.15% -765.89%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.18% 0.00% 0.00% 0.00% 0.00% 0.00% 50.01% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Agios Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Agios Pharmaceuticals' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 58,592,172.00 59,471,609.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 58,592,172.00 59,471,609.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -1.69 -1.69
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 64.80% 46.00% 28.35% 21.15% 51.06% 6.56% 44.57% 43.69% 86.09% 137.75% 259.25%
EBITDA Growth		 -4.31% -3.50% -12.92% 1,114.41% -24.85% -14.42% -20.02% -111.91% 5.59% -4.02% 14.04%
EBIT Growth		 -5.44% -3.33% -13.23% 1,089.30% -19.58% -15.81% -20.07% -111.85% 2.77% -4.30% 13.08%
NOPAT Growth		 24.99% -1.61% -12.93% -37.84% -17.65% -15.81% -20.07% 15.97% 2.77% -3.18% 12.99%
Net Income Growth		 -362.66% -0.66% -14.69% 1,137.97% -0.61% -9.49% -16.54% -110.91% -11.93% -11.00% 10.10%
EPS Growth		 -351.47% 1.36% -11.92% 1,089.02% 15.79% -6.90% -14.20% -110.97% -29.17% -9.03% 12.44%
Operating Cash Flow Growth		 -9.56% -4.92% -8.75% -36.62% -83.71% -11.64% -6.25% -4.67% 27.75% -6.67% 25.69%
Free Cash Flow Firm Growth		 22.55% -12.89% -22.01% 19.71% -22.02% -26.91% -44.33% -192.08% -14.23% -13.61% -4.38%
Invested Capital Growth		 21.85% 15.75% -12.12% -335.07% 91.69% 41.41% 98.18% 179.85% 221.30% 51.84% 102.95%
Revenue Q/Q Growth		 -4.00% 15.29% 5.20% 4.05% 19.70% -18.68% 42.73% 3.41% 55.02% 3.90% 115.68%
EBITDA Q/Q Growth		 -6.76% 9.95% -12.87% 1,034.82% -113.14% 17.47% -20.17% 8.62% -4.18% 10.14% -0.48%
EBIT Q/Q Growth		 -4.88% 11.95% -13.21% 1,046.22% -112.68% 14.72% -19.16% 8.02% -4.03% 9.60% -0.48%
NOPAT Q/Q Growth		 -5.33% 13.37% -14.93% -31.43% 10.10% 14.72% -19.16% 8.02% -4.03% 9.50% -0.48%
Net Income Q/Q Growth		 -5.05% 15.00% -17.87% 1,086.20% -110.18% 7.49% -25.46% 7.67% -4.45% 8.26% -1.61%
EPS Q/Q Growth		 -4.27% 15.20% -16.55% 1,059.76% -108.88% -7.64% -24.52% 7.77% -4.49% 9.14% 0.00%
Operating Cash Flow Q/Q Growth		 -17.59% -37.77% 27.31% -16.02% -58.12% 16.28% 30.82% -14.30% -9.15% -23.60% 51.81%
Free Cash Flow Firm Q/Q Growth		 -23.44% 8.97% -5.10% 32.02% -87.61% 5.32% -19.52% -37.58% 26.63% 5.83% -9.81%
Invested Capital Q/Q Growth		 -67.79% 536.38% -48.65% -323.31% 126.27% 369.47% -28.04% -10.02% 5.70% 121.87% -3.82%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 91.75% 92.34% 82.65% 91.27% 88.26% 87.57% 86.33% 86.96% 90.59% 93.64% 93.30%
EBITDA Margin		 -1,457.89% -1,138.73% -1,221.75% 10,976.53% -1,204.90% -1,222.77% -1,029.44% -909.70% -611.33% -528.71% -246.31%
Operating Margin		 -1,496.23% -1,124.34% -1,228.29% -1,146.93% -1,165.30% -1,221.97% -1,020.12% -907.37% -608.89% -530.34% -247.07%
EBIT Margin		 -1,472.11% -1,124.34% -1,209.96% 11,003.18% -1,165.30% -1,221.97% -1,020.12% -907.37% -608.89% -529.77% -246.81%
Profit (Net Income) Margin		 -1,350.70% -995.84% -1,115.71% 10,574.69% -899.56% -1,023.25% -899.40% -803.05% -541.09% -477.74% -225.06%
Tax Burden Percent		 100.00% 98.04% 100.00% 94.69% 93.02% 98.62% 99.54% 100.00% 100.71% 100.00% 100.00%
Interest Burden Percent		 91.75% 90.35% 92.21% 101.49% 82.99% 84.91% 88.58% 88.50% 88.24% 90.18% 91.19%
Effective Tax Rate		 0.00% 0.00% 0.00% 5.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -6,628.12% -838.03% -1,655.05% 0.00% -4,384.34% -885.75% -1,286.82% 0.00% -1,224.87% -464.73% -372.39%
ROIC Less NNEP Spread (ROIC-NNEP)		 -6,625.86% -836.04% -1,652.28% 0.00% -4,383.57% -884.38% -1,284.49% 0.00% -1,223.17% -462.94% -370.37%
Return on Net Nonoperating Assets (RNNOA)		 6,596.48% 810.11% 1,619.21% 0.00% 4,358.26% 855.76% 1,255.79% 0.00% 1,206.35% 443.97% 356.25%
Return on Equity (ROE)		 -31.64% -27.92% -35.85% 53.65% -26.08% -29.99% -31.03% -27.57% -18.52% -20.76% -16.15%
Cash Return on Invested Capital (CROIC)		 -6,485.22% -1,010.70% -1,730.53% 0.00% -5,946.11% -1,265.38% -2,100.61% -1,452.38% -1,862.95% -672.07% -771.51%
Operating Return on Assets (OROA)		 -36.30% -33.04% -40.77% 258.43% -32.71% -37.63% -37.16% -25.58% -22.22% -25.54% -18.82%
Return on Assets (ROA)		 -33.30% -29.27% -37.59% 248.37% -25.25% -31.51% -32.76% -22.64% -19.75% -23.03% -17.16%
Return on Common Equity (ROCE)		 -31.64% -27.92% -35.85% 53.65% -26.08% -29.99% -31.03% -27.57% -18.52% -20.76% -16.15%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -47.40% -55.25% 41.45% 0.00% 45.41% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -74 -64 -74 -97 -88 -75 -89 -82 -85 -77 -77
NOPAT Margin		 -1,047.36% -787.04% -859.80% -1,086.07% -815.71% -855.38% -714.08% -635.16% -426.23% -371.24% -172.95%
Net Nonoperating Expense Percent (NNEP)		 -2.26% -1.98% -2.77% 82.53% -0.77% -1.37% -2.33% -1.48% -1.70% -1.79% -2.02%
Return On Investment Capital (ROIC_SIMPLE)		 -9.17% - - - -5.68% -5.09% -6.49% -6.37% -7.13% -6.94% -7.54%
Cost of Revenue to Revenue		 8.25% 7.66% 17.35% 8.73% 11.74% 12.43% 13.67% 13.04% 9.41% 6.36% 6.70%
SG&A Expenses to Revenue		 497.04% 378.73% 412.49% 429.91% 481.80% 475.90% 368.28% 320.45% 258.48% 232.84% 115.20%
R&D to Revenue		 1,090.93% 837.95% 898.44% 808.29% 771.76% 833.64% 738.18% 673.88% 441.01% 391.15% 225.17%
Operating Expenses to Revenue		 1,587.98% 1,216.68% 1,310.93% 1,238.20% 1,253.56% 1,309.53% 1,106.46% 994.33% 699.48% 623.99% 340.38%
Earnings before Interest and Taxes (EBIT)		 -105 -92 -104 986 -125 -107 -127 -117 -122 -110 -110
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -104 -93 -105 984 -129 -107 -128 -117 -122 -110 -110
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.53 2.20 3.71 1.55 1.22 1.14 1.41 1.82 1.33 1.79 2.15
Price to Tangible Book Value (P/TBV)		 1.53 2.20 3.71 1.55 1.22 1.14 1.41 1.82 1.33 1.79 2.15
Price to Revenue (P/Rev)		 46.40 55.58 78.20 76.90 51.35 45.33 47.13 52.07 29.38 30.01 22.44
Price to Earnings (P/E)		 0.00 0.00 0.00 3.75 2.78 2.52 2.96 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 26.68% 35.95% 39.67% 33.75% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 94.14 31.05 118.49 0.00 38.32 6.07 19.46 39.63 14.75 14.72 20.30
Enterprise Value to Revenue (EV/Rev)		 16.34 31.29 57.58 26.38 9.37 6.86 14.36 24.00 7.83 14.18 12.63
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.52 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.52 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -0.97 -0.98 -1.01 -0.99 -0.97 -0.98 -1.00 -0.99 -0.96 -0.96
Leverage Ratio		 1.14 1.12 1.14 1.11 1.11 1.09 1.11 1.09 1.08 1.06 1.08
Compound Leverage Factor		 1.04 1.02 1.05 1.13 0.92 0.92 0.98 0.97 0.96 0.96 0.98
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 5.33 8.32 11.72 11.62 9.48 11.61 11.55 13.93 9.07 15.43 15.57
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 12.27 12.84 10.09 8.99 11.90 18.50 14.48 13.82 11.46 14.19 10.22
Quick Ratio		 11.47 11.64 9.16 8.44 11.06 17.12 13.41 12.81 10.52 12.80 9.08
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -75 -68 -72 -49 -92 -87 -104 -143 -105 -99 -108
Operating Cash Flow to CapEx		 -30,977.78% -98,878.22% -45,942.41% -20,099.76% -13,771.15% -14,554.70% -8,814.17% -5,668.87% -8,590.45% -15,464.24% -4,728.71%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.03 0.03 0.02 0.03 0.03 0.04 0.03 0.04 0.05 0.08
Accounts Receivable Turnover		 10.70 11.24 10.41 15.31 10.55 10.90 9.35 11.00 7.36 6.78 7.84
Inventory Turnover		 0.21 0.17 0.17 0.16 0.18 0.18 0.18 0.20 0.21 0.20 0.26
Fixed Asset Turnover		 1.40 1.65 1.93 2.30 2.70 2.94 3.51 3.98 4.81 6.11 9.58
Accounts Payable Turnover		 0.20 0.30 0.31 0.23 0.32 0.37 0.35 0.31 0.36 0.48 0.46
Days Sales Outstanding (DSO)		 34.13 32.47 35.05 23.84 34.60 33.49 39.06 33.19 49.61 53.82 46.58
Days Inventory Outstanding (DIO)		 1,746.32 2,127.97 2,163.56 2,284.67 2,045.93 2,079.43 2,070.03 1,863.34 1,741.19 1,794.54 1,414.01
Days Payable Outstanding (DPO)		 1,798.77 1,224.31 1,183.22 1,589.96 1,157.79 982.22 1,041.61 1,169.58 1,006.64 762.09 785.29
Cash Conversion Cycle (CCC)		 -18.32 936.13 1,015.40 718.55 922.73 1,130.70 1,067.48 726.96 784.15 1,086.26 675.30
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 4.66 30 15 -34 8.93 42 30 27 29 64 61
Invested Capital Turnover		 6.33 1.06 1.92 -3.37 5.37 1.04 1.80 -13.09 2.87 1.25 2.15
Increase / (Decrease) in Invested Capital		 0.84 4.03 -2.10 -48 4.27 12 15 61 20 22 31
Enterprise Value (EV)		 438 920 1,803 867 342 254 587 1,075 423 937 1,242
Market Capitalization		 1,245 1,634 2,448 2,528 1,874 1,679 1,926 2,332 1,587 1,982 2,207
Book Value per Share		 $14.51 $13.19 $11.63 $28.59 $27.02 $25.60 $23.65 $22.10 $20.46 $18.93 $17.25
Tangible Book Value per Share		 $14.51 $13.19 $11.63 $28.59 $27.02 $25.60 $23.65 $22.10 $20.46 $18.93 $17.25
Total Capital		 811 744 661 1,627 1,541 1,467 1,370 1,284 1,193 1,109 1,026
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -806 -714 -645 -1,661 -1,532 -1,425 -1,339 -1,257 -1,164 -1,045 -965
Capital Expenditures (CapEx)		 0.23 0.10 0.16 0.42 0.97 0.77 0.88 1.56 1.12 0.77 1.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 14 -0.40 -50 -9.27 23 10 5.49 5.42 39 30
Debt-free Net Working Capital (DFNWC)		 766 612 569 955 884 916 949 958 860 776 647
Net Working Capital (NWC)		 766 612 569 955 884 916 949 958 860 776 647
Net Nonoperating Expense (NNE)		 22 17 22 -1,045 9.00 15 23 22 23 22 23
Net Nonoperating Obligations (NNO)		 -806 -714 -645 -1,661 -1,532 -1,425 -1,339 -1,257 -1,164 -1,045 -965
Total Depreciation and Amortization (D&A)		 1.01 -1.18 -1.02 -2.39 -4.25 -0.07 -1.16 -0.30 -0.49 0.22 0.22
Debt-free, Cash-free Net Working Capital to Revenue		 -41.19% 47.43% -1.28% -152.17% -25.39% 61.77% 24.75% 12.26% 10.03% 58.99% 30.38%
Debt-free Net Working Capital to Revenue		 2,855.31% 2,081.20% 1,819.11% 2,904.50% 2,423.27% 2,474.01% 2,321.84% 2,139.61% 1,591.48% 1,174.90% 658.39%
Net Working Capital to Revenue		 2,855.31% 2,081.20% 1,819.11% 2,904.50% 2,423.27% 2,474.01% 2,321.84% 2,139.61% 1,591.48% 1,174.90% 658.39%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.71) ($1.45) ($1.69) $16.65 ($1.65) ($1.55) ($1.93) ($1.78) ($1.86) ($1.69) ($1.69)
Adjusted Weighted Average Basic Shares Outstanding		 55.65M 56.38M 56.80M 56.94M 56.81M 57.46M 57.93M 58.14M 57.97M 58.78M 59.49M
Adjusted Diluted Earnings per Share		 ($1.71) ($1.45) ($1.69) $16.22 ($1.44) ($1.55) ($1.93) ($1.78) ($1.86) ($1.69) ($1.69)
Adjusted Weighted Average Diluted Shares Outstanding		 55.65M 56.38M 56.80M 58.43M 57.89M 57.46M 57.93M 58.14M 57.97M 58.78M 59.49M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 56.19M 56.77M 56.89M 57.03M 57.30M 57.92M 58.10M 58.31M 58.59M 59.47M 59.70M
Normalized Net Operating Profit after Tax (NOPAT)		 -74 -64 -74 -97 -88 -75 -89 -82 -85 -77 -77
Normalized NOPAT Margin		 -1,047.36% -787.04% -859.80% -1,086.07% -815.71% -855.38% -714.08% -635.16% -426.23% -371.24% -172.95%
Pre Tax Income Margin		 -1,350.70% -1,015.79% -1,115.71% 11,167.28% -967.06% -1,037.61% -903.60% -803.05% -537.28% -477.74% -225.06%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Agios Pharmaceuticals (NASDAQ: AGIO) shows a balance sheet that remains very liquid, but its operating results continue to reflect a heavy R&D-driven loss profile. The company ended Q1 2026 with a large cash and investment position, but quarterly operating cash burn remains substantial despite some improvement in revenue.

  • Strong liquidity position: AGIO held about $737 million in cash and short-term investments in Q1 2026, plus $308 million in long-term investments, giving it a sizable total asset base of $1.18 billion.
  • Balance sheet is lightly levered: Total liabilities were only $75.9 million, compared with $1.11 billion in total equity, leaving the company with a very low debt burden based on the data provided.
  • Revenue growth improved in the latest quarter: Q1 2026 revenue rose to $20.7 million from $20.0 million in Q4 2025 and $12.9 million in Q3 2025.
  • Investments continue to support cash generation: In Q1 2026, sales and maturities of investments helped offset operating losses and produced $141.3 million of investing cash inflow.
  • Cash balance increased quarter over quarter: Cash and equivalents rose to $113.6 million from $92.7 million in Q3 2025.
  • Gross margin remains positive: Q1 2026 gross profit was $19.4 million on $20.7 million of revenue, showing the company is still generating product or collaboration revenue above direct costs.
  • Equity has been reduced by accumulated losses and treasury stock: Retained earnings were negative at ($660.8 million), and treasury stock remained at ($802.5 million), which is typical for a development-stage biotech but still reflects years of losses and share repurchases/issuance activity.
  • Share count is relatively stable: Weighted average diluted shares in Q1 2026 were 58.8 million, only modestly above the 57.7 million range seen over the prior year.
  • Capital spending is minimal: Q1 2026 purchases of property and equipment were just $0.8 million, indicating limited near-term capex needs.
  • Operating losses remain large: Q1 2026 operating loss was ($110.0 million), only slightly better than ($121.6 million) in Q4 2025, so core operations are still deeply unprofitable.
  • Net losses are continuing: AGIO reported a Q1 2026 net loss of ($99.1 million), compared with ($108.0 million) in Q4 2025 and ($103.4 million) in Q3 2025.
  • Operating cash burn is significant: Cash from operations was ($118.9 million) in Q1 2026, following ($96.2 million) in Q4 2025 and ($88.2 million) in Q3 2025.
  • R&D and SG&A spending remain elevated: Q1 2026 research and development expense was $81.1 million and SG&A was $48.3 million, keeping total operating expenses high relative to revenue.
  • Revenue is still small compared with the cost base: Even with recent improvement, quarterly revenue of about $20.7 million is not close to covering operating expenses above $129 million.

Bottom line: AGIO appears financially positioned to keep funding operations for now thanks to its substantial cash and investment reserves, but investors should expect continued losses and negative operating cash flow until revenue scales meaningfully or expenses come down. The latest quarter showed modest top-line improvement, yet the core challenge remains the same: the company is still burning a lot of cash to support its pipeline and operations.

08/15/26 12:20 PM ETAI Generated. May Contain Errors.

Agios Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Agios Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Agios Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$412.78 million in 2025, rising from -$117.73 million in 2015. The previous period was $673.73 million in 2024. Check out Agios Pharmaceuticals' forecast to explore projected trends and price targets.

Agios Pharmaceuticals' total operating income in 2025 was -$472.13 million, based on the following breakdown:
  • Total Gross Profit: $47.68 million
  • Total Operating Expenses: $519.82 million

Over the last 10 years, Agios Pharmaceuticals' total revenue changed from $59.12 million in 2015 to $54.03 million in 2025, a change of -8.6%.

Agios Pharmaceuticals' total liabilities were at $104.11 million at the end of 2025, a 14.8% decrease from 2024, and a 38.9% increase since 2015.

In the past 10 years, Agios Pharmaceuticals' cash and equivalents has ranged from $70.50 million in 2018 to $203.13 million in 2021, and is currently $89.13 million as of their latest financial filing in 2025.

Over the last 10 years, Agios Pharmaceuticals' book value per share changed from 9.17 in 2015 to 20.46 in 2025, a change of 123.2%.


Related Companies

Financial statements for NASDAQ:AGIO last updated on 7/30/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel